Showing 2551-2560 of 3315 results for "".
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti
- Study: Pediatric Keratoconus Prevalence Higher than Believed; May Change Care Approachhttps://modernod.com/news/study-pediatric-keratoconus-prevalence-higher-than-believed-may-change-care-approach/2482171/A new study, published in the journal Eye and Contact Lens, found that by utilizing Scheimpflug tomography during a comprehensive eye examination clinicians identified keratoconus in a limited pediatric population at a far gre
- Industry Opticianry Organizations Announce Merger at Vision Expo Easthttps://modernod.com/news/industry-opticianry-organizations-announce-merger-at-vision-expo-east/2482169/The Opticians Association of America [OAA], and the National Federation of Opticianry Schools [NFOS], have completed a merger to create the "United Opticians Association [UOA]," a model Opticianry Association representing over 80,000 opticians and contact lens professionals throughout N
- NewSight Reality Unveils Transparent Optical Module (TOM) 2.0 at Vision Expo East 2024https://modernod.com/news/newsight-reality-unveils-transparent-optical-module-tom-20-at-vision-expo-east-2024/2482167/NewSight Reality (NSR), a provider of Augmented Reality (AR) technologies, announced the next generation of its Transparent Optical Module (TOM) 2.0 at the Vision Expo East meeting. Highlights of the new technology include a patented stray light shielding solution, active micro-len
- Alcon Launches Clareon Presbyopia Correcting IOLs in Indiahttps://modernod.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/Alcon announced the launch of the Clareon family of IOLs in India. Clareon is designed to deliver consistent visual outcomes and exceptional clarity that lasts and is features a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglist
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- Apellis Appoints Philip Ferrone, MD, as Chief Medical Retina Advisorhttps://modernod.com/news/apellis-appoints-philip-ferrone-md-as-chief-medical-retina-advisor/2482154/Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, MD, will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Reti
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officerhttps://modernod.com/news/vital-tears-appoints-joseph-tauber-md-as-chief-medical-officer/2482146/Vital Tears, a provider of autologous serum tears, has announced the appointment of Joseph Tauber, MD, as its Chief Medical Officer (CMO). In his new role, Dr. Tauber will lead Vital Tears’ research and development initiatives, provide physician education and training, and&nb